表紙
市場調査レポート

2017年までの中枢神経系疾患市場:多発性硬化症、大鬱病性障害、統合失調症が2010年の市場の半数を占める

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

発行 GBI Research 商品コード 219213
出版日 ページ情報 英文 230 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
2017年までの中枢神経系疾患市場:多発性硬化症、大鬱病性障害、統合失調症が2010年の市場の半数を占める Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
出版日: 2011年11月01日 ページ情報: 英文 230 Pages
概要

世界の中枢神経系疾患治療薬市場は、2010年に531億米ドル規模となりました。これは368億米ドルだった2002年と比べ、CAGR4.7%となります。寿命拡大に伴う世界的高齢化が今後もCNS疾患罹患人口の増加につながるとみられています。

当レポートでは、世界の中枢神経系疾患市場について調査分析し、市場全体の収益動向と欧米、日本の地域別環境、各疾患別市場の動向、製品開発パイプライン、参入企業のプロファイルと市場シェアなどをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 2017年までの中枢神経系疾患市場:イントロダクション

第3章 世界市場概要

  • イントロダクション
  • 収益
    • ジェネリック薬のシェア
    • 年間治療費
  • 主要製品

第4章 地域別環境

  • 地域別収益分析
  • 米国
  • 欧州主要5カ国
  • 日本

第5章 治療環境

  • アルツハイマー病
  • アルツハイマー病治療薬市場の促進因子と阻害因子
  • 注意欠陥過活動性障害(ADHD)
  • 注意欠陥過活動性障害(ADHD)市場の促進因子と阻害因子
  • 双極性障害
  • 双極性障害市場の促進因子と阻害因子
  • 糖尿病性神経障害
  • 糖尿病性神経障害治療薬市場の促進因子と阻害因子
  • てんかん
  • てんかん市場の促進因子と阻害因子
  • 不眠症
  • 不眠症市場の促進因子と阻害因子
  • 片頭痛
  • 片頭痛治療薬市場の促進因子と阻害因子
  • 多発性硬化症
  • 多発性硬化症治療薬市場の促進因子と阻害因子
  • パーキンソン病
  • パーキンソン病治療薬市場の促進因子と阻害因子
  • 統合失調症
  • 統合失調症治療薬市場の促進因子と阻害因子
  • 大鬱病性障害
  • 大鬱病性障害治療薬市場の促進因子と阻害因子

第6章 製品パイプライン評価

  • イントロダクション
    • アルツハイマー病
    • ADHD
    • 双極性障害
    • 糖尿病性神経障害
    • てんかん
    • 不眠症
    • 大鬱病性障害
    • 片頭痛
    • 多発性硬化症
    • パーキンソン病
    • 統合失調症
    • DNA登録化合物

第7章 競合環境

  • 市場シェア分析
    • Eli Lilly
    • Pfizer
    • AstraZeneca
    • Johnson & Johnson (J&J)
    • Teva

第8章 M&A環境

  • M&A契約(2010〜2010年)
  • ライセンシング契約
  • 共同開発契約

第9章 付録

図表

目次
Product Code: GBIHC130MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010", which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer's disease, multiple sclerosis, Parkinson's disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer's disease, multiple sclerosis, Parkinson's disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. Valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.

Scope

  • Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Teva, and Johnson & Johnson.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the CNS disease market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Companies Mentioned

  • Eli Lilly
  • Pfizer
  • AstraZeneca
  • Johnson & Johnson (J&J)
  • Teva

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 8
  • 1.2 List of Figures 12

2 CNS Disorder Therapeutic Market to 2017 - Introduction 15

  • 2.1 GBI Research Report Guidance 15

3 CNS Disorder Therapeutic Market to 2017 - Global Market Overview 16

  • 3.1 Introduction 16
  • 3.2 Revenue 17
    • 3.2.1 Generic Share 18
    • 3.2.2 Annual Cost of Treatment 19
  • 3.3 Top CNS Drug Products 20
    • 3.3.1 Seroquel (IR/XR) (quetiapine fumarate) 20
    • 3.3.2 Zyprexa (olanzapine) 20
    • 3.3.3 Cymbalta (duloxetine Hcl) 21
    • 3.3.4 Copaxone (glatiramer acetate) 21
    • 3.3.5 Lyrica (pregabalin) 22
    • 3.3.6 Abilify (aripiprazole) 22
    • 3.3.7 Avonex (Interferon beta-1a) 23
    • 3.3.8 Rebif (interferon beta-1a) 23
    • 3.3.9 Effexor (venlafaxine) 23
    • 3.3.10 Betaferon /Betaseron (Interferon beta-1b) 24

4 CNS Disorder Therapeutic Market to 2017 - Geographical Landscape 25

  • 4.1 Revenue Analysis by Geography 25
  • 4.2 The US 26
    • 4.2.1 Revenue 26
    • 4.2.2 Annual Cost of Treatment 27
  • 4.3 Top Five Countries of Europe 28
    • 4.3.1 Revenue 28
    • 4.3.2 Annual Cost of Treatment 30
  • 4.4 Japan 31
    • 4.4.1 Revenue 31
    • 4.4.2 Annual Cost of Treatment 32

5 CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape 33

  • 5.1 Alzheimer's Disease 33
    • 5.1.1 Introduction 33
    • 5.1.2 Revenue 35
    • 5.1.3 Annual Cost of Treatment 39
    • 5.1.4 Treatment Usage Patterns 40
  • 5.2 Drivers and Restraints to Alzheimer's Disease Market 42
    • 5.2.1 Drivers for Alzheimer's disease Market 42
    • 5.2.2 Restraints for Alzheimer's disease Market 43
  • 5.3 Attention Deficit Hyperactivity Disorder (ADHD) 43
    • 5.3.1 Introduction 43
    • 5.3.2 Revenue 45
    • 5.3.3 Annual Cost of Treatment 49
    • 5.3.4 Treatment Usage Patterns 50
  • 5.4 Drivers and Barriers to ADHD Market 52
    • 5.4.1 Drivers for ADHD Market 52
    • 5.4.2 Barriers for ADHD Market 52
  • 5.5 Bipolar Disorder 53
    • 5.5.1 Introduction 53
    • 5.5.2 Revenue 55
    • 5.5.3 Annual Cost of Treatment 58
    • 5.5.4 Treatment Usage Patterns 59
  • 5.6 Drivers and Barriers to Bipolar Disorder Market 61
    • 5.6.1 Drivers for Bipolar Disorder Market 61
    • 5.6.2 Barriers for Bipolar Disorder Market 61
  • 5.7 Diabetic Neuropathy 62
    • 5.7.1 Introduction 62
    • 5.7.2 Revenue 64
    • 5.7.3 Annual Cost of Treatment 67
    • 5.7.4 Treatment Usage Pattern 68
  • 5.8 Drivers and Restraints to Diabetic Neuropathy Market 70
    • 5.8.1 Drivers for Diabetic Neuropathy Market 70
    • 5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market 70
  • 5.9 Epilepsy 71
    • 5.9.1 Introduction 71
    • 5.9.2 Revenue 72
    • 5.9.3 Annual Cost of Treatment 75
    • 5.9.4 Treatment Usage Patterns 76
  • 5.10 Drivers and Barriers to Epilepsy Market 78
    • 5.10.1 Drivers for Epilepsy Market 78
    • 5.10.2 Barriers to Epilepsy Market 78
  • 5.11 Insomnia 79
    • 5.11.1 Introduction 79
    • 5.11.2 Revenue 81
    • 5.11.3 Annual Cost of Treatment 84
    • 5.11.4 Treatment Usage Patterns 85
  • 5.12 Drivers and Barriers to Insomnia Market 87
    • 5.12.1 Drivers for Insomnia Market 87
    • 5.12.2 Barriers for Insomnia Market 88
  • 5.13 Migraine 88
    • 5.13.1 Introduction 88
    • 5.13.2 Revenue 90
    • 5.13.3 Annual Cost of Treatment 94
    • 5.13.4 Treatment Usage Patterns 95
  • 5.14 Drivers and Barriers for Migraine Market 98
    • 5.14.1 Drivers for Migraine Market 98
    • 5.14.2 Barriers for Migraine Market 99
  • 5.15 Multiple Sclerosis 99
    • 5.15.1 Introduction 99
    • 5.15.2 Revenue 102
    • 5.15.3 Annual Cost of Treatment 106
    • 5.15.4 Treatment Usage Patterns 107
  • 5.16 Drivers and Restraints to Multiple Sclerosis Therapeutics Market 109
    • 5.16.1 Drivers for Multiple Sclerosis Market 109
    • 5.16.2 Restraints for Multiple Sclerosis Market 110
  • 5.17 Parkinson's Disease 110
    • 5.17.1 Introduction 110
    • 5.17.2 Revenue 112
    • 5.17.3 Annual Cost of Treatment 115
    • 5.17.4 Treatment Usage Patterns 116
  • 5.18 Drivers and Restraints to Parkinson's Disease Therapeutics Market 118
    • 5.18.1 Drivers for the Parkinson's disease Therapeutics Market 118
    • 5.18.2 Restraints for the Parkinson's disease Therapeutics Market 118
  • 5.19 Schizophrenia 119
    • 5.19.1 Introduction 119
    • 5.19.2 Revenue 121
    • 5.19.3 Annual Cost of Treatment 124
    • 5.19.4 Treatment Usage Pattern 125
  • 5.20 Drivers and Barriers to Schizophrenia Market 127
    • 5.20.1 Drivers for Schizophrenia Market 127
    • 5.20.2 Barriers for Schizophrenia Market 128
  • 5.21 Major Depressive Disorder (MDD) 128
    • 5.21.1 Introduction 128
    • 5.21.2 Revenue 130
    • 5.21.3 Annual Cost of Treatment 133
    • 5.21.4 Treatment Usage Patterns 134
  • 5.22 Drivers and Barriers to MDD Market 136
    • 5.22.1 Drivers for MDD Market 136
    • 5.22.2 Barriers for MDD Market 136

6 Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 138

  • 6.1 Introduction 138
    • 6.1.1 Product Pipeline by Indication 138
    • 6.1.2 Product Pipeline by Clinical Stage of Development 139
  • 6.2 Alzheimer's disease 140
    • 6.2.1 Introduction 140
  • 6.3 Attention Deficit Hyperactivity Disorder (ADHD) 150
    • 6.3.1 Introduction 150
  • 6.4 Bipolar Disorder 153
    • 6.4.1 Introduction 153
  • 6.5 Diabetic Neuropathy 155
    • 6.5.1 Introduction 155
  • 6.6 Epilepsy 157
    • 6.6.1 Introduction 157
  • 6.7 Insomnia 161
    • 6.7.1 Introduction 161
  • 6.8 Major Depressive Disorder (MDD) 163
    • 6.8.1 Introduction 163
  • 6.9 Migraine 167
    • 6.9.1 Introduction 167
  • 6.10 Multiple Sclerosis 169
    • 6.10.1 Introduction 169
  • 6.11 Parkinson's Disease 175
    • 6.11.1 Introduction 175
  • 6.12 Schizophrenia 182
    • 6.12.1 Introduction 182
  • 6.13 NDA Filed Molecules 186
    • 6.13.1 Alzheimer's disease 186
    • 6.13.2 Bipolar Disorder 187
    • 6.13.3 Epilepsy 189
    • 6.13.4 Insomnia 191
    • 6.13.5 MDD 193
    • 6.13.6 Migraine 194
    • 6.13.7 Parkinson's disease 195
    • 6.13.8 Multiple sclerosis 195

7 CNS Disorder Therapeutic Market to 2017 - Competitive Landscape 198

  • 7.1 Market Share Analysis 198
    • 7.1.1 Eli Lilly 199
    • 7.1.2 Pfizer 200
    • 7.1.3 AstraZeneca 201
    • 7.1.4 Johnson & Johnson (J&J) 202
    • 7.1.5 Teva 203

8 CNS Disorder Therapeutic Market to 2017 - M&A Landscape 204

  • 8.1 M&A Deals (2010-2011) 204
    • 8.1.1 M&A Deals by Region 204
    • 8.1.2 M&A Deals by Indication 205
    • 8.1.3 M&A Deals by Value 206
    • 8.1.4 Deal Summary of M&A Deals by Value 209
  • 8.2 Licensing Deals 212
    • 8.2.1 Deal Summary 216
  • 8.3 Co-development Deals 218
    • 8.3.1 Deal Summary 220

9 CNS Disorder Therapeutic Market to 2017 - Appendix 223

  • 9.1 Market Definitions 223
  • 9.2 Abbreviations 223
  • 9.3 Research Methodology 224
    • 9.3.1 Coverage 224
    • 9.3.2 Secondary Research 225
    • 9.3.3 Primary Research 225
    • 9.3.4 Therapeutic Landscape 226
    • 9.3.5 Geographical Landscape 229
    • 9.3.6 Pipeline Analysis 229
    • 9.3.7 Competitive Landscape 229
    • 9.3.8 Expert Panel Validation 229
  • 9.4 Contact Us 229
  • 9.5 Disclaimer 229
  • 9.6 Sources 230

List of Tables

  • Table 1: CNS Disorder Therapeutic Market, Global, Revenue ($bn), 2002-2010 17
  • Table 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2010-2017 17
  • Table 3: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2010 18
  • Table 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2010-2017 18
  • Table 5: CNS Disorder Therapeutic Market, The US, Revenue ($m), 2002-2010 25
  • Table 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast($m), 2010-2017 25
  • Table 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2010 26
  • Table 8: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2010-2017 26
  • Table 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 28
  • Table 10: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017 28
  • Table 11: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 29
  • Table 12: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 29
  • Table 13: CNS Disorder Therapeutic Market, Japan, Revenue ($m), 2002-2010 30
  • Table 14: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2010-2017 30
  • Table 15: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2010 31
  • Table 16: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2010-2017 31
  • Table 17: CNS Disorder Therapeutic Market, Alzheimer's Disease, FDA Approved Cholinesterase Inhibitors, 2010 33
  • Table 18: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue ($bn), 2002-2010 34
  • Table 19: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2010-2017 34
  • Table 20: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2010 36
  • Table 21: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2010-2017 36
  • Table 22: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2010 38
  • Table 23: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2010-2017 38
  • Table 24: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 39
  • Table 25: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 40
  • Table 26: CNS Disorder Therapeutic Market, ADHD, Global Revenue ($m), 2002-2010 45
  • Table 27: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2010-2017 45
  • Table 28: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2010 46
  • Table 29: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2010-2017 46
  • Table 30: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2010 48
  • Table 31: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2010-2017 48
  • Table 32: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2010 49
  • Table 33: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2010-2017 50
  • Table 34: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue ($m), 2002-2010 54
  • Table 35: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2010-2017 54
  • Table 36: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2010 55
  • Table 37: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2010-2017 56
  • Table 38: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010 57
  • Table 39: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017 57
  • Table 40: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2010 58
  • Table 41: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2010-2017 59
  • Table 42: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue ($m), 2002-2010 63
  • Table 43: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast($m), 2010-2017 63
  • Table 44: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2010 64
  • Table 45: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2010-2017 65
  • Table 46: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2010 66
  • Table 47: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2010-2017 66
  • Table 48: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2010 67
  • Table 49: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2010-2017 68
  • Table 50: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue ($m), 2002-2010 71
  • Table 51: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2010-2017 71
  • Table 52: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2002-2010 72
  • Table 53: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2010-2017 73
  • Table 54: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2010 74
  • Table 55: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2010-2017 74
  • Table 56: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2010 75
  • Table 57: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2010-2017 76
  • Table 58: CNS Disorder Therapeutic Market, Insomnia, Global Revenue ($m), 2002-2010 80
  • Table 59: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast($m), 2010-2017 80
  • Table 60: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2010 81
  • Table 61: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2010-2017 82
  • Table 62: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2010 83
  • Table 63: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2010-2017 83
  • Table 64: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2010 84
  • Table 65: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2010-2017 85
  • Table 66: CNS Disorder Therapeutic Market, Migraine, Global Revenue ($m), 2002-2010 89
  • Table 67: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast($m), 2010-2017 90
  • Table 68: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2002-2010 91
  • Table 69: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2010-2017 91
  • Table 70: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2010 93
  • Table 71: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2010-2017 93
  • Table 72: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2010 95
  • Table 73: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2010-2017 95
  • Table 74: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue ($m), 2002-2010 102
  • Table 75: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2010-2017 102
  • Table 76: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2010 103
  • Table 77: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2010-2017 104
  • Table 78: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2010 105
  • Table 79: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2010-2017 105
  • Table 80: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2010 106
  • Table 81: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2010-2017 107
  • Table 82: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Revenue ($m), 2002-2010 111
  • Table 83: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Revenue Forecast ($m), 2010-2017 111
  • Table 84: CNS Disorder Therapeutic Market, Parkinson's Disease, Revenue by Country ($m), 2002-2010 112
  • Table 85: CNS Disorder Therapeutic Market, Parkinson's Disease, Revenue by Country ($m), 2010-2017 113
  • Table 86: CNS Disorder Therapeutic Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2010 114
  • Table 87: CNS Disorder Therapeutic Market, Parkinson's Disease, Annual Cost of Treatment ($), 2010-2017 114
  • Table 88: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 115
  • Table 89: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 116
  • Table 90: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue ($m), 2002-2010 120
  • Table 91: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2010-2017 120
  • Table 92: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2010 121
  • Table 93: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2010-2017 122
  • Table 94: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 123
  • Table 95: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017 123
  • Table 96: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2010 124
  • Table 97: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2010-2017 125
  • Table 98: CNS Disorder Therapeutic Market, MDD, Global Revenue ($m), 2002-2010 129
  • Table 99: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast ($m), 2010-2017 130
  • Table 100: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2010 130
  • Table 101: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2010-2017 131
  • Table 102: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2010 132
  • Table 103: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2010-2017 132
  • Table 104: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2002-2010 133
  • Table 105: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2010-2017 134
  • Table 106: CNS Disorder Therapeutic Market, Alzheimer's Disease, Discovery Product Pipeline, 2011 140
  • Table 107: CNS Disorder Therapeutic Market, ADHD Product Pipeline, 2011 150
  • Table 108: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline, 2011 153
  • Table 109: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline, 2011 155
  • Table 110: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline, 2011 157
  • Table 111: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline, 2011 161
  • Table 112: CNS Disorder Therapeutic Market, MDD, Product Pipeline, 2011 163
  • Table 113: CNS Disorder Therapeutic Market, Migraine, Product Pipeline, 2011 167
  • Table 114: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline, 2011 169
  • Table 115: CNS Disorder Therapeutic Market, Parkinson's Disease, Product Pipeline, 2011 175
  • Table 116: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline, 2011 182
  • Table 117: CNS Disorder Therapeutic Market, Global, M&A Deals ($m), 2010-2011 206
  • Table 118: CNS Disorder Therapeutic Market, Global, Announced M&A Deals ($m), 2010-2011 207
  • Table 119: CNS Disorder Therapeutic Market, Global, Licensing Deals ($m), 2010-2011 212
  • Table 120: CNS Disorder Therapeutic Market, Co-developments, 2010-2011 218

List of Figures

  • Figure 1: CNS Disorder Therapeutic Market, Global, Revenue Share by Indication (%), 2010 16
  • Figure 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2002-2017 17
  • Figure 3: CNS Disorder Therapeutic Market, Global, Generic Share (%), 2010 and 2017 18
  • Figure 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2017 19
  • Figure 5: CNS Disorder Therapeutic Market, Revenue by Geography (%),2010 25
  • Figure 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast ($m), 2002-2017 26
  • Figure 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2017 27
  • Figure 8: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 28
  • Figure 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 30
  • Figure 10: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2002-2017 31
  • Figure 11: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2017 32
  • Figure 12: CNS Disorder Therapeutic Market, Alzheimer's Disease Treatment Algorithm 34
  • Figure 13: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2002-2017 35
  • Figure 14: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2017 36
  • Figure 15: CNS Disorder Therapeutic Market, Alzheimer's Disease, Generic Share in Alzheimer's Disease Market, 2010 and 2017 38
  • Figure 16: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2017 39
  • Figure 17: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 40
  • Figure 18:CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Market Drivers and Restraints, 2010-2017 42
  • Figure 19: CNS Disorder Therapeutic Market, ADHD Treatment Algorithm 44
  • Figure 20: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2002-2017 46
  • Figure 21: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2017 47
  • Figure 22: CNS Disorder Therapeutic Market, ADHD, Generic Share in ADHD Market, 2010 and 2017 48
  • Figure 23: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2017 49
  • Figure 24: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2017 50
  • Figure 25: CNS Disorder Therapeutic Market, ADHD, Global Market Drivers and Barriers, 2010-2017 52
  • Figure 26: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm 54
  • Figure 27: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2002-2017 55
  • Figure 28: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2017 56
  • Figure 29: CNS Disorder Therapeutic Market, Bipolar Disorder, Generic Share in Bipolar Disorder Market, 2010 and 2017 57
  • Figure 30: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017 58
  • Figure 31: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2017 59
  • Figure 32: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017 61
  • Figure 33: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm 63
  • Figure 34: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast ($m), 2002-2017 64
  • Figure 35: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2017 65
  • Figure 36: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Generic Share in Diabetic Neuropathy Market ($m), 2010 and 2017 66
  • Figure 37: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2017 67
  • Figure 38: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2017 68
  • Figure 39: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Market Drivers and Restraints, 2010-2017 70
  • Figure 40: CNS Disorder Therapeutic Market, Epilepsy, Treatment Algorithm 71
  • Figure 41: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2002-2017 72
  • Figure 42: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m),2002-2017 73
  • Figure 43: CNS Disorder Therapeutic Market, Epilepsy, Generic Share in Epilepsy Market, 2010 and 2017 74
  • Figure 44: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2017 75
  • Figure 45: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2017 76
  • Figure 46: CNS Disorder Therapeutic Market, Epilepsy, Global Market Drivers and Barriers, 2010-2017 78
  • Figure 47: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm 80
  • Figure 48: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast ($m), 2002-2017 81
  • Figure 49: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2017 82
  • Figure 50: CNS Disorder Therapeutic Market, Insomnia, Generic Share in Insomnia Market, 2010 and 2017 83
  • Figure 51: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2017 84
  • Figure 52: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2017 85
  • Figure 53: CNS Disorder Therapeutic Market, Insomnia, Global Market Drivers and Barriers, 2010-2017 87
  • Figure 54: CNS Disorder Therapeutic Market, Migraine, Treatment Algorithm 89
  • Figure 55: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast ($m), 2002-2017 90
  • Figure 56: CNS Disorder Therapeutic Market, Mirgaine, Revenue by Country ($m), 2002-2017 91
  • Figure 57: CNS Disorder Therapeutic Market, Migraine, Generic Share in Migraine Market, 2010 and 2017 93
  • Figure 58: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2017 94
  • Figure 59: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2017 95
  • Figure 60: CNS Disorder Therapeutic Market, Migraine, Global Market Drivers and Barriers, 2010-2017 98
  • Figure 61: CNS Disorder Therapeutic Market, Multiple Sclerosis (RRMS), Treatment Algorithm 101
  • Figure 62:CNS Disorder Therapeutic Market, Multiple Sclerosis (PRMS), Treatment Algorithm 102
  • Figure 63: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2002-217 103
  • Figure 64: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2017 104
  • Figure 65: CNS Disorder Therapeutic Market, Multiple Sclerosis, Generic Share in Multiple Sclerosis Market, 2010 and 2017 105
  • Figure 66: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2017 106
  • Figure 67: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2017 107
  • Figure 68: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017 109
  • Figure 69: CNS Disorder Therapeutic Market, Parkinson's Disease, Treatment Algorithm 111
  • Figure 70: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Revenue Forecast($m), 2002-2017 112
  • Figure 71: CNS Disorder Therapeutic Market, Parkinson's Disease, Revenue by Country ($m), 2002-2017 113
  • Figure 72: CNS Disorder Therapeutic Market, Parkinson's Disease, Generic Share in Parkinson's Disease Market ($m), 2010 and 2017 114
  • Figure 73: CNS Disorder Therapeutic Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2017 115
  • Figure 74: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 116
  • Figure 75: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Market Drivers and Restraints, 2010-2017 118
  • Figure 76: CNS Disorder Therapeutic Market, Schizophrenia, Treatment Algorithm 120
  • Figure 77: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2002-2017 121
  • Figure 78: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2017 122
  • Figure 79: CNS Disorder Therapeutic Market, Schizophrenia, Generic Share in Schizophrenia Market, 2010 and 2017 123
  • Figure 80: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 124
  • Figure 81: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2017 125
  • Figure 82: CNS Disorder Therapeutic Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017 127
  • Figure 83: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm 129
  • Figure 84: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast($m), 2002-2017 130
  • Figure 85: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2017 131
  • Figure 86: CNS Disorder Therapeutic Market, MDD, Generic Share in MDD Market, 2010 and 2017 132
  • Figure 87: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2017 133
  • Figure 88: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Pattern (Thousand), 2002-2017 134
  • Figure 89: CNS Disorder Therapeutic Market, MDD, Global Market Drivers and Barriers, 2010-2017 136
  • Figure 90: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline by Indication (%),2011 138
  • Figure 91: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline by Clinical Stage of Development (%),2011 139
  • Figure 92: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline (%),2011 140
  • Figure 93: CNS Disorder Therapeutic Market, ADHD, Product Pipeline (%), 2011 150
  • Figure 94: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline (%),2011 153
  • Figure 95: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline (%),2011 155
  • Figure 96: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline (%),2011 157
  • Figure 97: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline (%), 2011 161
  • Figure 98: CNS Disorder Therapeutic Market, MDD, Product Pipeline (%),2011 163
  • Figure 99: CNS Disorder Therapeutic Market, Migraine, Product Pipeline (%), 2011 167
  • Figure 100: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline (%), 2011 169
  • Figure 101: CNS Disorder Therapeutic Market, Parkinson's Disease, Product Pipeline (%), 2011 175
  • Figure 102: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline (%), 2011 182
  • Figure 103: CNS Disorder Therapeutic Market, Global Top Companies Share (%), 2010 198
  • Figure 104: CNS Disorder Therapeutic Market, SWOT Analysis of Eli Lilly, 2010 199
  • Figure 105: CNS Disorder Therapeutic Market, SWOT Analysis of Pfizer, 2010 200
  • Figure 106: CNS Disorder Therapeutic Market, SWOT Analysis of AstraZeneca, 2010 201
  • Figure 107: CNS Disorder Therapeutic Market, SWOT Analysis of Johnson & Johnson, 2010 202
  • Figure 108: CNS Disorder Therapeutic Market, SWOT Analysis of Teva 203
  • Figure 109: CNS Disorder Therapeutic Market, Global M&A Deals by Region, 2010-2011 204
  • Figure 110: CNS Disorder Therapeutic Market, Global M&A Deals by Indication, 2010-2011 205
  • Figure 111: CNS Disorder Therapeutic Market, Global, M&A Deals by Value ($m), 2010-2011 206
  • Figure 112: CNS Disorder Therapeutic Market, Licensing Deals, by Indication, 2010-2011 212
  • Figure 113: CNS Disorder Therapeutic Market, Co-developments by Indication, 2010-2011 218
  • Figure 114: GBI Research Market Forecasting Model 228
Back to Top